EpiLAB is a company that sells a portable tuberculosis diagnosis test helping health organizations fighting TB by bridging the diagnosis gap and downscaling contamination. The test leverages a state of the art patented microbiology technology which ensures high sensibility testing while being affordable for development countries which accounts for 80% of TB cases. EpiLAB is incubated at Ecole Polytechnique, a top engineering school in France and is looking for good deed investments and partners to finalize its diagnosis kit and penetrate its markets.
|Stage||Startup stage EST October 2020|
|Sectors||Biotechnology and medical research, Medical equipment and supplies|
|Markets||Angola, Botswana, Central African Republic, Congo, Congo, Democratic Republic of the, Côte d'Ivoire, Ethiopia, Ghana, Kenya, Lesotho, Namibia, Nigeria, Sierra Leone, South Africa, Tanzania, United Republic of, Zambia, Zimbabwe|
|Customer model||B2B2G, Governments (B2G)|
|Contact||Login to view details|